Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma
Share
Why It Matters
Regeneron's cancer medicine Libtayo helped people live longer. This positive news shows the drug is working well in real-world tests.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.